Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

A biotech company called Alnylam announced today that a small clinical trial for a genetic therapy based on RNA interference, or RNAi, suggests that the technique can have a powerful effect on its target gene. The therapeutic effect lasted for over a month with just one dose. The company is also working with a medical device maker, Medtronic, on a way to deliver RNAi treatment directly to the brain, in order to treat the degenerative brain disease Huntington’s.

The patients in the trial have a genetic disorder that originates in the liver and leads to the buildup of protein deposits in many organs. Alnylam, a Cambridge, Massachusetts-based company, says its RNAi therapeutic, given at its highest dose, reduces the amount of the faulty protein that spurs the disease by almost 94 percent.

The positive results add weight to the notion that RNAi therapeutics could eventually help patients with a range of genetic diseases. RNAi therapy involves researchers producing snippets of RNA, a close relative of DNA, that match a portion of a gene of interest. When administered, this so-called small interfering RNA (siRNA) causes the destruction of that gene’s products before it can be turned into a protein. The specificity of RNAi for targeting particular genes has attracted a lot of interest from people who want to use it as a clinical treatment (see “Prescription RNA”).

“Today’s platforms target the protein that causes the disease and bind to that protein. We stop the protein from being made in the first place,” says Barry Greene, president and chief operating officer of Alnylam.

But a recurring challenge for the therapeutic RNAi field is how to deliver the siRNAs to the right place in the body. On their own, the small molecules do not survive long in the bloodstream, so simply injecting a patient with a solution of unprotected siRNAs is not effective. “The key technical hurdle is getting the siRNA [inside] the right cells,” says Greene.

For several of its projects, Alnylam uses nanoparticles to protect and deliver its siRNAs, which can then be delivered by injection. But for genetic diseases that originate in the brain, the body’s own defenses, namely the blood-brain barrier, complicate delivery further. To circumvent the blood-brain barrier, which prevents most molecules from leaving the bloodstream and entering the brain, Alnylam has looked to a different delivery mechanism: direct dosing of unpackaged siRNAs.

Medtronic, a Minneapolis company that designs and manufactures medical devices, has devised a way to allow this. Together, the companies have developed a treatment that combines Alnylam’s RNAi therapeutic with Medtronic’s drug delivery technology to treat Huntington’s.

Alnylam Pharmaceuticals

Huntington’s, for which there is no cure, is caused by the loss of neurons due to a toxic protein made by a tainted gene. The idea behind the new treatment is to stop at least some of that protein’s production so that it cannot damage the brain. 

The treatment would use a device made by Medtronic that is already implanted in more than 250,000 patients to treat chronic pain and spasticity. The device features a catheter connected to a drug pump that’s surgically implanted into the abdomen. The pump pushes drugs through the device and into the fluid around the spinal cord. In the case of the Huntington’s RNAi work, the system is adapted to deliver liquids directly into the brain tissue.

“To create pressure, it actively pumps the drug into the brain, and that pressure really moves the drug into the brain and further away than the drugs would otherwise go based on diffusion,” says Lothar Krinke, vice president and manager of Medtronic’s deep brain stimulation projects.

In a study published earlier this year, the researchers showed that the device can distribute the siRNA to around six cubic centimeters of brain tissue in a rhesus monkey. The results of the study suggest the treatment was safe over 28 days of infusion and showed that the protein product of the Huntington’s-type gene in the monkeys was nearly halved, says Krinke.

Medtronic is currently leading the effort to push the device-drug treatment into the clinic. Although the company will not say when it anticipates initiating clinical trials, the work has been funded by CHDI, a nonprofit foundation focused on developing cures for Huntington’s.

1 comment. Share your thoughts »

Credits: Alnylam Pharmaceuticals

Tagged: Biomedicine, RNA, RNAi, siRNA

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me